The PDX/Biospecimen Core B provides part of the infrastructure support for the P01 Projects. It has been designed to meet the needs of these projects and serve as a stand-alone resource for collaborative efforts. The Core B will provide a well-organized and standardized system of specimen collection, storage, distribution and related clinical/research information dissemination. There will be consistency and quality assurance in the pathological analysis of tissue specimens. Specimens from our repository, our LuCaP prostate cancer PDXs and clinical specimens, particularly those from our rapid autopsy program (e.g. prostate cancer bone metastases) have been and will continue to be distributed to other prostate cancer investigators on a national and international basis. The Core B Specific Aims are: 1) Maintain and Distribute Patient-Derived Prostate Cancer Xenografts, 2) Collect and Distribute Clinical Biopecimens (i.e. tissues, including those from surgery and the rapid autopsy program, serum, plasma and urine), processing, quality control, storage, distribution and database entry, 3) Establish and Maintain Specimen Quality and Core B Service Efficiency Programs, 4) Provide Specialized Pathology and Laboratory Services, including production of tissue microarrays, interpretation of immunohistology by urologic pathologists, production of specimen derivatives and perform PSA immunoassays for research, 5) Administrative Program to obtain samples from minorities, prioritize the distribution of specimens, ensure patient confidentiality and compliance with IRB requirements, and continually improve quality control measures.
The performance of translational research mandates that investigators have ready access to well- characterized clinically and biologically relevant models, and well documented clinical specimens. The PDX/Biospecimen Core B directors have decades of experience in recognizing these needs and providing such services not only to local investigators but to those who request specimens on a world-wide basis, and these interactions will continue.
|Chen, Sen; Cai, Changmeng; Sowalsky, Adam G et al. (2018) BMX-Mediated Regulation of Multiple Tyrosine Kinases Contributes to Castration Resistance in Prostate Cancer. Cancer Res 78:5203-5215|
|Lam, Hung-Ming; Corey, Eva (2018) Supraphysiological Testosterone Therapy as Treatment for Castration-Resistant Prostate Cancer. Front Oncol 8:167|
|Beshiri, Michael L; Tice, Caitlin M; Tran, Crystal et al. (2018) A PDX/Organoid Biobank of Advanced Prostate Cancers Captures Genomic and Phenotypic Heterogeneity for Disease Modeling and Therapeutic Screening. Clin Cancer Res 24:4332-4345|
|Russo, Joshua W; Liu, Xiaming; Ye, Huihui et al. (2018) Phosphorylation of androgen receptor serine 81 is associated with its reactivation in castration-resistant prostate cancer. Cancer Lett 438:97-104|
|Mostaghel, Elahe A (2018) Alternative Acts: Oncogenic Splicing of Steroidogenic Enzymes in Prostate Cancer. Clin Cancer Res :|
|Uo, Takuma; Plymate, Stephen R; Sprenger, Cynthia C (2018) The potential of AR-V7 as a therapeutic target. Expert Opin Ther Targets 22:201-216|
|Arai, Seiji; Jonas, Oliver; Whitman, Matthew A et al. (2018) Tyrosine Kinase Inhibitors Increase MCL1 Degradation and in Combination with BCLXL/BCL2 Inhibitors Drive Prostate Cancer Apoptosis. Clin Cancer Res 24:5458-5470|
|Viswanathan, Srinivas R; Ha, Gavin; Hoff, Andreas M et al. (2018) Structural Alterations Driving Castration-Resistant Prostate Cancer Revealed by Linked-Read Genome Sequencing. Cell 174:433-447.e19|
|Russo, Joshua W; Gao, Ce; Bhasin, Swati S et al. (2018) Downregulation of Dipeptidyl Peptidase 4 Accelerates Progression to Castration-Resistant Prostate Cancer. Cancer Res 78:6354-6362|
|Sowalsky, Adam G; Ye, Huihui; Bhasin, Manoj et al. (2018) Neoadjuvant-Intensive Androgen Deprivation Therapy Selects for Prostate Tumor Foci with Diverse Subclonal Oncogenic Alterations. Cancer Res 78:4716-4730|
Showing the most recent 10 out of 90 publications